KalVista Pharmaceuticals, Inc. presents data for its oral Factor XIIa (FXIIa) and plasma kallikrein (PKa) inhibitor programs at the KININ2022 conference in Annecy, France. Presentations for oral FXIIa inhibitors shows that the compounds block the initiation and amplification of the kallikrein kinin system (KKS) in preclinical models. Of note, small molecule FXIIa inhibitors were shown to suppress FXII zymogen enzyme activity, which has been recently implicated as a distinct initiator of KKS activation, and thus may contribute to disease.

“The oral FXIIa inhibitors we are evaluating show great promise by blocking the earliest steps of kallikrein kinin system activation,” says Andrew Crockett, CEO of KalVista. “The discovery of potent, selective, and orally available FXIIa inhibitors may provide novel therapeutic opportunities to treat HAE and other KKS-mediated diseases.”
(Source: KalVista)